51 results about "Ipratropium bromide" patented technology

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.< / PTEXT>

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

The invention belongs to the technical field of textile auxiliaries and discloses a propofol phosphate gas defoamer. The propofol phosphate gas defoamer is prepared from the following components in parts by weight: 0.1 to 0.8 part of propofol phosphate, 0.5 to 1.7 parts of ipratropium bromide, 100 to 150 parts of nitrogen, 15 to 20 parts of helium, 1 to 4 parts of oxygen, 0.1 to 1.5 parts of carbonic oxide, 12 to 14 parts of argon and 10 to 15 parts of ethanol. The preparation method of the propofol phosphate gas defoamer comprises the following steps: dissolving propofol phosphate into an ethanol solution, heating and stirring at the temperature of 30 to 40 DEG, collecting evaporation gas and mixing the evaporation gas with nitrogen; then mixing the mixed gas with isopropyl ammonium bromide aerosol, subsequently carrying out ultraviolet irradiation treatment for 1 to 2 hours, and mixing a treated mixture with other gases, thus obtaining a finished product. The gas defoamer is introduced into the bottom of a working bath for use, wherein the use amount of working solution per liter is 1 to 2L per minute; by means of adding gas, the dispersion uniformity of the working bath is improved; at the same time, a good foam eliminating and inhibiting effect is achieved; the propofol phosphate gas defoamer can be recycled and is high in economic benefit.

The present invention relates to a novel process for the preparation of anticholinergic agents / drugs, such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide, ipratropium bromide (V), in a continuous flow mode in the presence of one or more polar protic solvents. The anticholinergic agents are useful in the treatment of respiratory diseases, such as asthma or chronic obstructive pulmonary disease (COPD), in a form suitable for inhalation.

The invention discloses a compound doxofylline solution for inhalation and a preparation method thereof. The components of the compound doxofylline solution for inhalation include crude drug, isotonicity regulator, antioxidant, pH regulator and water for injection , the crude drug comprises a mixture of doxofylline and ipratropium bromide. The compound doxofylline solution for inhalation of the present invention is suitable for patients who need the combined application of multiple bronchodilators, and is used for the treatment of reversible bronchospasm related to airway obstructive diseases. Compared with the prior art, the quality is more stable , Medication is safer and more convenient.